Company / Operating Cash Flow
ORAMED PHARMACEUTICALS INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$8.4M
FY2025
5-year range
-$27.9M / -$8.4M
FY2021-FY2025
Trend
+18.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$28M in FY2023 to $5M in FY2018.
Based on SEC 10-K filings.
-$8M in FY2025.
Improved from -$28M to -$8M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 18.3% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.4M | +18.3% |
| FY2024 | -$10.3M | +63.1% |
| FY2023 | -$27.9M | -31.8% |
| FY2022 | -$21.2M | -70.3% |
| FY2021 | -$12.4M | +3.9% |
| FY2020 | -$12.9M | -121.9% |
| FY2019 | -$5.8M | -225.3% |
| FY2018 | $4.7M | +194.1% |
| FY2017 | -$4.9M | -21.6% |
| FY2016 | -$4.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026